Skip to main content
← All trials
AtherosclerosisHeart and circulationDrugPhase 3

What this study is

Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a).

Participation will last about 120 weeks.

What's being tested

  • Lepodisiran

    Intervention · DRUG

  • Placebo

    Intervention · DRUG

Both interventions

Administered SC

Study details

Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event
Sponsor
Eli Lilly and Company
Conditions
Atherosclerosis · Cardiovascular Diseases · Lipoprotein(a)
Enrolling
252 people
Starts
2026-06-01
Est. completion
2029-12
Design
Double-blind, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗